此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

DYNE-101 在 1 型强直性营养不良参与者中的安全性、耐受性、药效学、疗效和药代动力学研究 (ACHIEVE)

2026年9月19日 更新者:Dyne Therapeutics

一项随机、安慰剂对照、多剂量递增研究,评估 DYNE-101 对 1 型强直性肌营养不良症参与者的安全性、耐受性、药效学、疗效和药代动力学

The primary purpose of the study is to evaluate the safety and tolerability of multiple intravenous (IV) doses of DYNE-101 administered to participants with Myotonic Dystrophy Type 1 (DM1).

The study consists of 4 periods: A Screening Period (up to 8 weeks), a Placebo-Controlled Period (24 weeks), a Treatment Period (24 weeks) and a Long-Term Extension (LTE) Period (208 weeks) in both multiple-ascending dose (MAD) and dose expansion cohorts.

研究概览

地位

主动,不招人

研究类型

介入性

注册 (实际的)

127

阶段

  • 阶段2
  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Berlin、德国、10117
        • Charité - Universitätsmedizin Berlin
      • Munich、德国、80336
        • Ludwig Maximilians University, Munich - Friedrich Baur Institut
      • Milan、意大利、20162
        • Centro Clinico Nemo
      • Rome、意大利、00168
        • Fondazione Policlinico Universitario A Gemelli-Rome
      • Auckland、新西兰、1023
        • NZCR Auckland
      • Nantes、法国、44093
        • CHU de Nantes
      • Paris、法国、75013
        • Institut de Myologie
    • Victoria
      • Fitzroy、Victoria、澳大利亚、3065
        • St. Vincent's Hospital
    • California
      • Stanford、California、美国、94305
        • Stanford University
    • Florida
      • Gainesville、Florida、美国、32610
        • University of Florida College of Medicine
    • Indiana
      • Indianapolis、Indiana、美国、46202
        • Indiana University School of Medicine
    • Iowa
      • Iowa City、Iowa、美国、52242
        • University of Iowa
    • Missouri
      • St Louis、Missouri、美国、63110
        • Washington University in St. Louis
    • New York
      • Rochester、New York、美国、14642
        • University of Rochester Medical Center
    • Texas
      • Denton、Texas、美国、76208
        • Neurology Rare Disease Center
    • Virginia
      • Richmond、Virginia、美国、23298
        • Virginia Commonwealth University (VCU)
      • London、英国、NW1 2BU
        • University College London Hospitals
      • Newcastle upon Tyne、英国
        • John Walton Muscular Dystrophy Research Centre
      • Salford、英国、M6 8HD
        • Salford Royal Hospital
      • Nijmegen、荷兰
        • Radboud Medical Center

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 65年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Diagnosis of DM1 with trinucleotide repeat size >100.
  • Age of onset of DM1 muscle symptoms ≥12 years.
  • Clinically apparent myotonia equivalent to hand opening time of at least 2 seconds in the opinion of the Investigator.
  • Hand grip strength and ankle dorsiflexion strength.
  • Able to complete 10-MWRT, stair ascend/descend (MAD cohorts only), and 5×STS at screening without the use of assistive devices such as canes, walkers, or orthoses.

Exclusion Criteria:

  • History of major surgical procedure within 12 weeks prior to the start of investigative product administration or an expectation of a major surgical procedure (eg, implantation of cardiac defibrillator) during the study.
  • History of anaphylaxis.
  • Medical condition other than DM1 that would significantly impact ambulation or participation in functional assessments.
  • Treatment with medications that can improve myotonia within a period of 5 half-lives of the medication prior to performing screening assessments.
  • Electrocardiogram (ECG) with the corrected QT interval by Fridericia's Formula (QTcF) ≥450 milliseconds (ms) in men and QTcF ≥460 ms in women, PR ≥240 ms, left bundle-branch block, or a conduction defect, which is clinically significant in the opinion of the Investigator.
  • Percent predicted forced vital capacity (FVC) <50%.
  • History of tibialis anterior biopsy within 3 months of Day 1 or planning to undergo tibialis anterior biopsies during study period for reasons unrelated to the study.
  • Participant has a history of suicide attempt, suicidal behavior, or has any suicidal ideation within 6 months prior to Screening that meets criteria at a level of 4 or 5 of the Columbia Suicide Severity Rating Scale (C-SSRS) or who, in the opinion of the Investigator, is at significant risk to commit suicide.
  • Use of glucagon-like peptide 1 (GLP-1) agonist medications including semaglutide, dulaglutide, liraglutide, exenatide, or tirzepatide within a period of 5 half-lives of the medication prior to performing screening assessments.
  • Significant weight loss during study participation may impact weight-based dosing, performance on muscle function assessments, and pharmacodynamic (PD) biomarkers.

Note: Other inclusion and exclusion criteria may apply.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:顺序分配
  • 屏蔽:四人间

武器和干预

参与者组/臂
干预/治疗
实验性的:MAD Cohort: Placebo-Controlled Period: DYNE-101

Participants will be randomized to receive ascending doses of DYNE-101, once every 4 weeks (Q4W) or once every 8 weeks (Q8W) for up to 24 weeks.

Administered by IV infusion

安慰剂比较:MAD Cohort: Placebo-Controlled Period: Placebo

Participants will be randomized to receive DYNE-101 matching placebo, Q4W or Q8W for up to 24 weeks.

Administered by IV infusion

实验性的:MAD Cohort: Treatment Period: DYNE-101

Participants who receive DYNE-101 in Placebo-Controlled Period will continue to receive DYNE-101, Q4W or Q8W for up to 24 weeks.

Participants who receive placebo in Placebo-Controlled Period will receive DYNE-101, Q4W or Q8W for up to 24 weeks.

Administered by IV infusion

Administered by IV infusion

实验性的:MAD Cohort: Long-Term Extension Period: DYNE-101

Participants will receive DYNE-101, Q4W or Q8W for up to 208 weeks.

Administered by IV infusion

实验性的:Dose Expansion Cohort: Placebo-Controlled Period: DYNE-101

Participants will receive DYNE-101, Q8W for up to 24 weeks.

Administered by IV infusion

实验性的:Dose Expansion Cohort: Placebo-Controlled Period: Placebo

Participants will receive DYNE-101 matching placebo, Q8W for up to 24 weeks.

Administered by IV infusion

实验性的:Dose Expansion Cohort: Treatment Period: DYNE-101

Participants who receive DYNE-101 in Placebo-Controlled Period will continue to receive DYNE-101, Q8W for up to 24 weeks.

Participants who receive placebo in Placebo-Controlled Period will receive DYNE-101, Q8W for up to 24 weeks.

Administered by IV infusion

Administered by IV infusion

实验性的:Dose Expansion Cohort: Long-Term Extension Period: DYNE-101

Participants will receive DYNE-101, Q8W for up to 208 weeks.

Administered by IV infusion

研究衡量的是什么?

主要结果指标

结果测量
大体时间
剂量扩展队列:通过视频打开时间(VHOT)来衡量的Myotonia的基线变化
大体时间:基线到第25周
基线到第25周
MAD Cohorts: Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
大体时间:Through study completion, up to Week 257
Through study completion, up to Week 257

次要结果测量

结果测量
大体时间
MAD队列:从肌肉组织中肌酸肌酸蛋白激酶(DMPK)核糖核酸(RNA)表达的基线变化
大体时间:基线到第45周
基线到第45周
疯狂的队列:从基线在手抓握放松时间中变化
大体时间:基线到第121周
基线到第121周
疯狂的队列:从楼梯式ASCEND/DESCEND测试中的基线更改
大体时间:基线到第121周
基线到第121周
MAD队列:反义寡核苷酸(ASO)肌肉组织中的Dyne-101浓度
大体时间:直到第45周
直到第45周
疯狂队列:从骨骼肌组织中的复合替代剪接指数(CASI)中的基线变化
大体时间:基线到第45周
基线到第45周
剂量膨胀队列:从CASI中的基线变化骨骼肌肉组织
大体时间:基线到第25周
基线到第25周
剂量扩展队列:从QMT总数的基线变化
大体时间:基线到第25周
基线到第25周
剂量扩展队列:从10-mwrt中的基线变化
大体时间:基线到第25周
基线到第25周
剂量扩展队列:从基线变化5×STS
大体时间:基线到第25周
基线到第25周
剂量扩展队列:从9-HPT中的基线变化
大体时间:基线到第25周
基线到第25周
剂量扩展队列:从肌发育性营养不良健康指数(MDHI)总分的基线变化
大体时间:基线到第25周
基线到第25周
剂量扩张队列:患者全球变化印象(PGI-C)
大体时间:基线到第25周
基线到第25周
临床医生全球变化印象(CGI-C)
大体时间:基线到第25周
基线到第25周
剂量扩展队列:从患者全球严重程度(PGI-S)的基线变化(PGI-S)
大体时间:基线到第25周
基线到第25周
剂量扩张队列:从临床医生全球严重程度印象(CGI-S)的基线变化(CGI-S)
大体时间:基线到第25周
基线到第25周
剂量扩展队列:从MDHI子量表分数中的基线变化
大体时间:基线到第25周
基线到第25周
剂量膨胀队列:从基线在Myotonic营养不良1型活动和参与量表(DM1-ACTIV^C)总分
大体时间:基线到第25周
基线到第25周
剂量扩展队列:从基线(以百分比为预测的手柄强度)变化
大体时间:基线到第25周
基线到第25周
MAD Cohorts: Change From Baseline in Myotonia as Measured by vHOT
大体时间:Baseline up to Week 257
Baseline up to Week 257
MAD Cohorts: Change From Baseline in Quantitative Myometry Testing (QMT)
大体时间:Baseline up to Week 257
Baseline up to Week 257
MAD Cohorts: Change From Baseline in 10-Meter Walk/Run Test (10-MWRT)
大体时间:Baseline up to Week 257
Baseline up to Week 257
MAD Cohorts: Change From Baseline in 5 Times Sit to Stand (5×STS)
大体时间:Baseline up to Week 257
Baseline up to Week 257
MAD Cohorts: Change From Baseline in 9-Hole Peg Test (9-HPT)
大体时间:Baseline up to Week 257
Baseline up to Week 257
MAD Cohorts: Maximum Observed Plasma Drug Concentration (Cmax) of DYNE-101
大体时间:Pre-dose, and at multiple timepoints up to Week 257
Pre-dose, and at multiple timepoints up to Week 257
MAD Cohorts: Time to Maximum Observed Plasma Concentration (tmax) of DYNE-101
大体时间:Pre-dose, and at multiple timepoints up to Week 257
Pre-dose, and at multiple timepoints up to Week 257
MAD Cohorts: Area Under the Concentration-time Curve From Hour 0 to the Last Measurable Plasma Concentration (AUCtlast) of DYNE-101
大体时间:Pre-dose, and at multiple timepoints up to Week 257
Pre-dose, and at multiple timepoints up to Week 257
MAD Cohorts: Area Under the Concentration-time Curve Extrapolated to Infinity (AUC∞) of DYNE-101 in Plasma
大体时间:Pre-dose, and at multiple timepoints up to Week 257
Pre-dose, and at multiple timepoints up to Week 257
MAD Cohorts: Apparent Terminal Elimination Rate Constant (λz) of DYNE-101 in Plasma
大体时间:Pre-dose, and at multiple timepoints up to Week 257
Pre-dose, and at multiple timepoints up to Week 257
MAD Cohorts: Apparent Terminal Elimination Half-Life (t1/2) of DYNE-101 in Plasma
大体时间:Pre-dose, and at multiple timepoints up to Week 257
Pre-dose, and at multiple timepoints up to Week 257
MAD Cohorts: Clearance (CL) of DYNE-101 in Plasma
大体时间:Pre-dose, and at multiple timepoints up to Week 257
Pre-dose, and at multiple timepoints up to Week 257
MAD Cohorts: Volume of Distribution at the Terminal Phase (Vz) of DYNE-101 in Plasma
大体时间:Pre-dose, and at multiple timepoints up to Week 257
Pre-dose, and at multiple timepoints up to Week 257
MAD Cohorts: Volume of Distribution at Steady State (Vss) of DYNE-101 in Plasma
大体时间:Pre-dose, and at multiple timepoints up to Week 257
Pre-dose, and at multiple timepoints up to Week 257
MAD Cohorts: Number of Participants With Antidrug Antibodies (ADAs)
大体时间:Up to Week 257
Up to Week 257

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2022年9月5日

初级完成 (估计的)

2029年7月1日

研究完成 (估计的)

2029年7月1日

研究注册日期

首次提交

2022年7月28日

首先提交符合 QC 标准的

2022年7月28日

首次发布 (实际的)

2022年8月1日

研究记录更新

最后更新发布 (实际的)

2026年9月23日

上次提交的符合 QC 标准的更新

2026年9月19日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

是的

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅